Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.44 |
| ▸ | HTR2B | P41595 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | HCN1 | O60741 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016757 | 1.00 | HTR2C (0.44) | HTR2CHTR2BHTR2AOPRM1HCRTR1 | |
| SCHEMBL16586799 | 1.00 | HTR2C (0.44) | HTR2CHTR2BHTR2AOPRM1HCRTR1 | |
| SCHEMBL16586800 | 1.00 | HTR2C (0.44) | HTR2CHTR2BHTR2AOPRM1HCRTR1 | |
| SCHEMBL15254790 | 0.84 | HTR2C (0.63) | HTR2CHTR2BHTR2A | |
| SCHEMBL15254788 | 0.84 | HTR2C (0.63) | HTR2CHTR2BHTR2A | |
| SCHEMBL16590861 | 0.84 | HTR2C (0.49) | HTR2CHTR2BHTR2AHCRTR1HCRTR2 | |
| SCHEMBL7058800 | 0.81 | OPRM1 (0.40) | HTR2CHTR2BHTR2AOPRM1HCRTR1 | |
| SCHEMBL18016882 | 0.81 | HTR2C (0.49) | HTR2CHTR2BHTR2AOPRM1HCRTR1 | |
| SCHEMBL16585302 | 0.79 | HTR2C (0.69) | HTR2CHTR2BHTR2A | |
| SCHEMBL18016760 | 0.79 | HTR2C (0.69) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |